News Center

Home page

Peak Report

News reports

Jianfeng Group Pro 2017-018 (Announcement of Resolution of 14th Session of 9th Board of Directors)

Release time:

2020-08-05

Securities Code: 600668 Securities Abbreviations: Jianfeng Group No.: Pro 2017-018

Bond Abbreviations: 13 Peak 01 Bond Code: 122227

Bond Abbreviations: 13 Peak 02 Bond Code: 122344

Zhejiang Jianfeng Group Co., Ltd.

Ninth Session 14 Board Resolution Announcement

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents .

1. Board Meeting

(I) The convening and convening of this board meeting complies with relevant laws, regulations and the relevant provisions of the company's Articles of Association.

(II) 2017# On July 26, 38, the company issued the notice of this board meeting by telephone, fax, e-mail and personal delivery.

(III) 2017# On August 2, 42, the board meeting was held by means of communication voting.

(IV) 9

directors who should attend this board meeting and 9 directors who actually attended the meeting.

2. the deliberation of the board meeting

, and passed the "Proposal on Related Party Transactions for Equity Reorganization in Shanya South"

. The board of directors deliberated and passed the proposal, agreeing to carry out equity restructuring of Hangzhou Shanya South Cement Co., Ltd. (hereinafter referred to as "

Shanya South"). Mr. Jiang Xiaomeng, an affiliated director of

, avoided voting on the motion.

Voting result: 8

votes in favor, 0 votes against and 0 abstentions.

For details, please refer to the Announcement on Related Party Transactions on the Equity Reorganization of Shanya South (P.2017 -019

The independent directors of the Company considered the matter in advance and concluded that the

connected transaction was essentially intended to reduce the corporate hierarchy and improve operational efficiency. The relevant information on the related party transaction is complete. The price of the related party transaction is based on the book value of the long-term equity investment of Southern Peak in Shanya South as contained in the audit report of Tianzi International Certified Public Accountants (Tiangong Zi [2017]9406 ), which is qualified to practice securities. The transaction amount is calculated according to the proportion of shares of Southern Peak respectively held by Peak Cement and Jinhua South. The price of the transaction is fair and reasonable. After the completion of the transaction, the overall interest of the transferee will remain unchanged. The related party transactions above

did not harm the interests of the company and its shareholders, and agreed to submit the above proposal to the 14th

th meeting of the ninth board of directors of the company for deliberation.

The Audit Committee of the Board of Directors issued an audit opinion on the matter: it is of the opinion that (1

) the relevant information on the related transaction is complete and the management of the Company has conducted comprehensive communication with us. The price of the equity transaction is fair and reasonable, and the transaction follows the principle of openness and fairness. (2 ) The equity transfer of this connected transaction is essentially an equity restructuring implemented to reduce the corporate hierarchy and improve operational efficiency, with Peak Cement and Southern Peak, a subsidiary of Golden South China, transferring the equity held by them, and the transferee parties determining the amount of equity transfer based on the same valuation basis and in proportion to the equity of Southern Peak. After the completion of the reorganization, the overall interest of the transferee remains unchanged. (3) This connected transaction was conducted in strict accordance with relevant legal procedures, in compliance with relevant laws and regulations and the relevant provisions of the Articles of Association, and there was no harm to the interests of the Company or shareholders. The Committee agrees to this related transaction.

The independent directors of the Company expressed their independent opinion on the resolution and concluded that:(1

) the price of the connected transaction was fair and reasonable and there was no harm to the interests of the Company and its shareholders. It is conducive to optimizing the equity structure of the company's long-term equity investment, reducing the shareholding level and improving the operational efficiency of the enterprise. (2) The amount of this related party transaction is 62,099,765 yuan, which does not exceed 5% of the absolute value of the company's latest audited net assets. It needs to be submitted to the company's board of directors for deliberation, and does not need to be submitted to the general meeting of shareholders for deliberation. The proposal was reviewed and approved at the 14th meeting of the ninth board of directors of the company. The related director Jiang Xiaomeng avoided voting. The review and voting procedures were legal and effective, and met the requirements of the "Articles of Association" and other laws, regulations and regulatory documents.

is hereby announced

Zhejiang Jianfeng Group Co., Ltd.

Board of Directors

August 2, 2017

More information

The company fully deploys 2018 work

On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals

2020

07-30

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise

On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

The company was rated as an advanced unit of the city's focus on talent and love talent.

News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)

2020

07-31

< 1...38 39 40...61 > 跳转到页